Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.

@article{Kiess2012AdjuvantTR,
  title={Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.},
  author={Ana P. Kiess and Heather L. McArthur and Kathleen M. Mahoney and Sujata Patil and Patrick Glyn Morris and Alice Y. Ho and Clifford A. Hudis and Beryl M McCormick},
  journal={Cancer},
  year={2012},
  volume={118 8},
  pages={1982-8}
}
BACKGROUND Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer have a higher risk of locoregional recurrence (LRR), even in the setting of early stage, lymph node-negative disease. In this sequential, retrospective study, the authors evaluated whether adjuvant trastuzumab was associated with reduced LRR in women with lymph node-negative, HER2-positive disease who received breast-conservation therapy (BCT). METHODS By using an institutional database, 197 women… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…